New serine biomarkers show promise for early Alzheimer's detection, linking tau assemblies to cognitive decline and offering ...

Researchers say CSF biomarker test correlates with the severity of cognitive decline, independent of other factors, including brain amyloid deposition.

Enter SynPull, a new synaptosome imaging method developed by David Klenerman, John Danial, and colleagues at the University of Cambridge, England. SynPull combines single-molecule pull-down of ...

Alzheimer's disease (AD) pathology begins decades before clinical onset of dementia. Amyloid beta (Aβ) generally accumulates first in cognitively normal (CN) individuals, with tau and cognitive ...

Sweden Background Alzheimer's disease (AD) pathology is found in a considerable portion of patients with Parkinson's disease (PD), particularly those with early dementia (PDD). Altered cerebrospinal ...

Prolonged rapid eye movement latency may be a potential marker for Alzheimer disease and Alzheimer disease and related dementias.

Researchers from the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) have found that tau protein and beta-amyloid – two pathological hallmarks of Alzheimer’s disease – ...

A reporter uncovers evidence that research fraud on a massive scale has hyped the potential benefit of expensive drugs aimed ...

Feb. 6, 2025 — A research team has discovered that the two key pathological hallmarks of Alzheimer's -- tau protein and beta-amyloid -- affect brain circuits in distinct yet synergistic ways ...

TauRx was an early proponent of the notion that tau protein could be a legitimate drug target in Alzheimer's, since it was taken up by a lot of larger companies, including Roche/UCB, Johnson ...

▎药明康德内容团队编辑 实验室介绍阿尔兹海默病（Alzheimer’s disease, AD）是最常见的神经退行性疾病，是全球最具挑战的攻坚课题之一。AD根据临床表现可以分为临床前期和症状期。淀粉样蛋白（Aβ）沉积出现在临床前病理期，比症状期早15-20年。对比之下，神经原纤维缠结（Tau ...